Company profile
BioVaxys Technology Corp.
OTC: BVAXF · Healthcare · Biotechnology
Canadian filerHQ Etobicoke, BCReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 28
v0.1 · 5/100 weight · pillars only
↑ disclosure history, market scale · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$2.9M
Employees
3
as of 2026-08-24
Market cap
$2.6M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2024
Net income-$2.9M-4.0M CAD2024
Operating income-$2.3M-3.1M CAD2024
Total assets$934.7k1.3M CAD2024
Liabilities$2.3M3.2M CAD2024
Equity-$1.4M-1.9M CAD2024
Revenue trend
FY2019 – FY2024 · USD
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BioVaxys Technology Corp.’s revenue?
BioVaxys Technology Corp. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Autonomix Medical, Inc.28DEco-Growth Strategies Inc.——Indo Global Exchange(s) PTE, Ltd.——VitaSpring Biomedical Co. Ltd.18DPsyence Group Inc.——Lifeline Biotechnologies, Inc.——Key facts
CEOJames Christopher Passin
SectorHealthcare
IndustryBiotechnology
HeadquartersEtobicoke, BC
ExchangeOTC: BVAXF
Employees3
IPO date2018-12-28
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.